• Publications
  • Influence
Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis
Background:  Natalizumab has been recommended for the treatment of patients with relapsing remitting multiple sclerosis with insufficient response to interferon‐beta (IFN‐beta) or glatiramer acetateExpand
  • 44
  • 4
Secondary myelodysplastic syndrome following long-term treatment with azathioprine in patients with multiple sclerosis
Azathioprine (Aza) is a widely used immunosuppressive drug in multiple sclerosis (MS) treatment. Recently, the incidence of secondary myelodysplastic syndromes (sMDS) associated with a poor prognosisExpand
  • 14
Mitoxantrone Does Not Restore the Impaired Suppressive Function of Natural Regulatory T Cells in Patients Suffering from Multiple Sclerosis
CD4+CD25+ regulatory T (Treg) cells play a major role in controlling autoimmunity by suppressing self-reactive T cells. Multiple sclerosis (MS) is an inflammatory demyelinating disorder of theExpand
  • 8
Effect of functional NMDA-antagonist flupirtine on automatic postural responses in Parkinson's disease
Abstract. Animal studies have demonstrated potent antiparkinsonian and other motor effects of the functional NMDA-antagonist flupirtine and suggest a therapeutic use in Parkinson's disease (PD). InExpand
  • 10